Moxetumomab Pasudotox
drugOn this page
Also known as CAT-8015HA-22HA22LumoxitiMoxetumomab pasudotox tdfkMoxetumomab pasudotox-tdfk
Summary
Moxetumomab Pasudotox (CHEMBL1743043) is an approved antibody drug conjugate (ATC L01FB02) targeting CD22; indicated across 8 conditions including hairy cell leukemia and neoplasm.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Antibody drug conjugate
- ATC class: L01FB02
- Targets: 1 (CD22)
- Indications: 8 conditions
- Clinical trials: 12
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1743043 |
| Name | Moxetumomab Pasudotox |
| Type | Antibody drug conjugate |
| Max phase | 4 |
| ATC | L01FB02 |
Also known as: CAT-8015, HA-22, HA22, Lumoxiti, Moxetumomab pasudotox, Moxetumomab pasudotox tdfk, Moxetumomab pasudotox-tdfk, MOXETUMOMAB PASUDOTOX
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| CD22 | CD22 | Binding | 8.22 | 0.2% | P20273 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): CD22.
Top Reactome pathways
6 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Adaptive Immune System | 1 | CD22 |
| Immune System | 1 | CD22 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 1 | CD22 |
| CD22 mediated BCR regulation | 1 | CD22 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | 1 | CD22 |
| Signaling by the B Cell Receptor (BCR) | 1 | CD22 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| negative regulation of immunoglobulin production | 1 |
| cell adhesion | 1 |
| regulation of endocytosis | 1 |
| regulation of B cell proliferation | 1 |
| B cell activation | 1 |
| regulation of immune response | 1 |
| negative regulation of calcium-mediated signaling | 1 |
| negative regulation of B cell receptor signaling pathway | 1 |
| negative regulation of immune system process | 1 |
| negative regulation of signal transduction | 1 |
Indications & clinical
Indications
8 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| hairy cell leukemia | 4 | MONDO:0018935 | EFO:1000956 |
| neoplasm | 4 | MONDO:0005070 | EFO:0000616 |
| acute lymphoblastic leukemia | 2 | MONDO:0004967 | EFO:0000220 |
| leukemia | 1 | MONDO:0005059 | EFO:0000565 |
| lymphoma | 1 | MONDO:0005062 | EFO:0000574 |
| non-Hodgkin lymphoma | 1 | MONDO:0018908 | EFO:0005952 |
| B-cell chronic lymphocytic leukemia | 1 | MONDO:0004948 | EFO:0000095 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 12.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1 | 7 |
| PHASE2 | 2 |
| PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01829711 | PHASE3 | COMPLETED | Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia |
| NCT01030536 | PHASE1/PHASE2 | COMPLETED | Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL) |
| NCT02227108 | PHASE2 | TERMINATED | Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma |
| NCT02338050 | PHASE2 | TERMINATED | Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation |
| NCT03805932 | PHASE1 | ACTIVE_NOT_RECRUITING | Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia |
| NCT00457860 | PHASE1 | UNKNOWN | Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease |
| NCT00462189 | PHASE1 | UNKNOWN | Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease |
| NCT00515892 | PHASE1 | UNKNOWN | Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease |
| NCT00587015 | PHASE1 | TERMINATED | A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Non-Hodgkin’s Lymphoma (NHL) |
| NCT00587457 | PHASE1 | TERMINATED | A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia |
| NCT01891981 | PHASE1 | TERMINATED | Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL) |
| NCT03501615 | Not specified | APPROVED_FOR_MARKETING | An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Genes: CD22
- Diseases: hairy cell leukemia, neoplasm